Time BioVentures

Phantom Neuro is a neurotechnology company dedicated to enhancing robotic limb rehabilitation through innovative muscle-machine interfaces. By integrating neurotechnology with robotic systems, the company focuses on improving mobility and facilitating precise control of robotic limbs, which allows for more natural movement and better user experiences. Phantom Neuro employs a minimally invasive approach, aiming to provide effective rehabilitation tools and improve the quality of life for individuals with mobility challenges. Additionally, the company explores various applications of its technologies, contributing to the advancement of assistive robotics and addressing the needs of individuals with limb differences.

Conceivable Life Sciences is a company focused on revolutionizing in vitro fertilization (IVF) through automation. It is developing the first fully automated IVF laboratory, which aims to democratize access to fertility treatments. By utilizing advanced technologies and single-cell robotics, Conceivable Life Sciences operates IVF labs designed to streamline the IVF process, thereby making it more accessible for individuals and couples seeking to fulfill their dreams of parenthood. The company's innovative approach seeks to enhance the efficiency and effectiveness of IVF, ultimately contributing to improved outcomes for patients.

Rivermark Medical is a medical device company focused on developing minimally invasive therapies for Benign Prostatic Hyperplasia (BPH), a condition that significantly impacts urinary function. The technology, created by urologists, aims to provide effective symptom relief while minimizing side effects and patient downtime. This innovative treatment allows for a swift return to normal daily activities, eliminating the need for post-procedural catheters and ensuring a reliable reduction in BPH symptoms. Rivermark Medical’s approach reflects a commitment to improving patient outcomes through advanced medical solutions.

Brightside Health is a telemedicine platform focused on mental health treatment for anxiety and depression. It delivers evidence-based care through video visits, messaging, ongoing support, and medication delivery, backed by a network of providers who conduct depression evaluation, treatment, and monitoring. The platform combines precision psychiatry with clinically proven therapy and continuous care monitoring to help patients achieve and maintain improvement. It supports communication, scheduling, and access to information about health and wellness related to depression, and tracks progress throughout treatment. Founded in 2017 and based in San Francisco.

Commons Clinic is a multispecialty healthcare provider based in Austin, Texas, founded in 2021. It delivers comprehensive specialty and surgical care for pain, orthopedics, women's health, and men's health. The company also develops a healthcare platform that combines preventive diagnostics with specialist-driven interventions, uniting advanced diagnostics, personalized care pathways, and interventional procedures within an accountable system across musculoskeletal care, women's health, and preventive oncology to support informed clinical decisions and improved patient outcomes.

BillionToOne Inc. is a precision diagnostics company focused on developing advanced genetic testing platforms that detect and quantify diseases at the molecular level. Established in 2016 and headquartered in Menlo Park, California, the company offers a noninvasive prenatal screening solution called UNITY, which analyzes fetal cell-free DNA from a single blood sample provided by the mother. This test can identify single-gene disorders such as cystic fibrosis, spinal muscular atrophy, and thalassemia, thereby providing a safer alternative to invasive procedures like amniocentesis. Beyond prenatal diagnostics, BillionToOne is also developing oncology assays that enable the detection of actionable mutations and monitor tumor burden through blood samples, allowing for more precise therapy selection and monitoring. The company's innovative technologies aim to make genetic testing both accurate and accessible, ensuring that a broader spectrum of patients can benefit from advanced medical diagnostics.

Phantom Neuro is a neurotechnology company dedicated to enhancing robotic limb rehabilitation through innovative muscle-machine interfaces. By integrating neurotechnology with robotic systems, the company focuses on improving mobility and facilitating precise control of robotic limbs, which allows for more natural movement and better user experiences. Phantom Neuro employs a minimally invasive approach, aiming to provide effective rehabilitation tools and improve the quality of life for individuals with mobility challenges. Additionally, the company explores various applications of its technologies, contributing to the advancement of assistive robotics and addressing the needs of individuals with limb differences.

BillionToOne Inc. is a precision diagnostics company focused on developing advanced genetic testing platforms that detect and quantify diseases at the molecular level. Established in 2016 and headquartered in Menlo Park, California, the company offers a noninvasive prenatal screening solution called UNITY, which analyzes fetal cell-free DNA from a single blood sample provided by the mother. This test can identify single-gene disorders such as cystic fibrosis, spinal muscular atrophy, and thalassemia, thereby providing a safer alternative to invasive procedures like amniocentesis. Beyond prenatal diagnostics, BillionToOne is also developing oncology assays that enable the detection of actionable mutations and monitor tumor burden through blood samples, allowing for more precise therapy selection and monitoring. The company's innovative technologies aim to make genetic testing both accurate and accessible, ensuring that a broader spectrum of patients can benefit from advanced medical diagnostics.

NanoMosaic is a biotechnology company focused on advancing early illness detection, prognostic monitoring, and biomarker identification through its innovative nanoneedle technology. The company's proprietary proteomic platform utilizes nanoneedles to enable precise protein detection and quantification. By integrating these capabilities onto a single chip, NanoMosaic aims to enhance the efficiency and accuracy of biomarker discovery and validation processes. This technology is designed to support the medical and healthcare industries in improving diagnostic capabilities and patient outcomes.

DeepSight Technology is a health technology company focused on enhancing diagnostic medical imaging through its innovative sensing technology. By integrating patented hardware, software, and artificial intelligence, DeepSight significantly improves image quality and extends the depth penetration of medical diagnostic ultrasounds. This advancement allows healthcare providers to utilize proprietary sensor technology that broadens the capabilities of diagnostic ultrasounds, ultimately benefiting public health and well-being. The company aims to make medical imaging safer, faster, more affordable, and more accessible, marking a substantial improvement in the field of diagnostic imaging.